Roche and Genentech invest $700+ million in new North Carolina manufacturing facility
Introduction:
Genentech, a subsidiary of the Roche Group, has revealed plans to invest more than $700 million in constructing a new, cutting-edge drug manufacturing facility in Holly Springs, North Carolina.
The facility will cover an area of approximately 700,000 square feet, reflecting a significant expansion in the company’s production capabilities.
Features:
This major investment is set to create over 400 high-paying manufacturing jobs once the facility is up and running, providing a boost to the local economy. Additionally, the construction phase is expected to generate more than 1,500 jobs, supporting a wide range of workers involved in building the site.
The new facility will be dedicated to producing next-generation medicines targeting obesity, a field where Roche and Genentech are focusing their future efforts.
While the initial investment is substantial, the company has indicated that it may increase the funding and size of the facility in response to evolving business demands and changes in the United States’ regulatory and policy landscape.
At present, Roche and Genentech maintain a considerable presence in the US, with 13 manufacturing sites and 15 research and development centres across their Pharmaceutical and Diagnostics divisions.
Together, these sites employ around 25,000 people across 24 locations in eight states, underlining the group’s significant commitment to healthcare innovation and manufacturing in the country.
Specifications:
| Name | New North Carolina Manufacturing Facility |
| Budget | $700+ Million |
| Type | Construction |
